Automated Accounts Payable provider Glantus Holdings raises 14M and successfully floats on AIM. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.40
Bid: 8.40
Ask: 8.96
Change: 0.05 (0.58%)
Spread: 0.56 (6.67%)
Open: 8.32
High: 8.48
Low: 8.32
Yest. Close: 8.63
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Immupharma raises £6.5m in oversubscribed placing

Wed, 2nd Sep 2020 09:25

(Sharecast News) - Drug discovery and development firm Immupharma has raised £6.5m, before fees, via an oversubscribed placing of 59.09m ordinary shares.
Immupharma said on Wednesday that its placing shares, which represented 24.3% of the company's enlarged share capital, were being listed a 10.0p each - a discount of 27.6% to their seven-day volume-weighted average price on 1 September.

The AIM-listed group will use the proceeds to progress its therapeutic pipeline - including BioAMP-B, a drug that it said offers a potential treatment for many serious and life-threatening fungal infections.

Immupharma highlighted that when raking into account existing cash resources and expected net proceeds of £5.9m, it now expects to have sufficient cash resources to fund operations through to the end of 2023.

Chairman Tim McCarthy said: "With a strong balance sheet, a diverse and exciting therapeutic pipeline and our lead drug candidate, Lupuzor moving forward into an international Phase III trial, ImmuPharma is in an extremely robust position.

"With value-enhancing news-flow over the next period, we are confident of creating long term shareholder value for all of our shareholders."

As of 0925 BST, Immupharma shares had sunk 15.08% to 13.80p.

More News

TRADING UPDATES: Keystone Law and Checkit post annual revenue growth

TRADING UPDATES: Keystone Law and Checkit post annual revenue growth

29 Apr 21 17:33

ImmuPharma clarifies next steps for phase 3 Lupuzor trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in the potentially life-threatening auto-immune disease systemic lupus erythematosus (SLE) on Tuesday.

9 Feb 21 14:13

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

9 Feb 21 10:42

No Conditional US Approval So Far For ImmuPharma Lupus Drug Lupuzor

No Conditional US Approval So Far For ImmuPharma Lupus Drug Lupuzor

9 Feb 21 10:36

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

24 Nov 20 21:30

IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

23 Nov 20 14:29

ImmuPharma gets December date for FDA meeting

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in systemic lupus erythematosus (SLE) on Friday, reporting that the US Food & Drug Administration (FDA) has now confirmed the date of 4 December for a Type 'A' Meeting Request.

20 Nov 20 12:15

ImmuPharma Partner To Discuss Progression Of Lupuzor Drug With US FDA

ImmuPharma Partner To Discuss Progression Of Lupuzor Drug With US FDA

20 Nov 20 11:04

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

10 Nov 20 17:40

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

30 Sep 20 18:37

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

29 Sep 20 18:19

IN BRIEF: Immupharma Repays Lind Global Convertible Security

IN BRIEF: Immupharma Repays Lind Global Convertible Security

22 Sep 20 21:17

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

11 Sep 20 14:09

ImmuPharma confirms continued FDA delays for Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.

11 Sep 20 12:17

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

2 Sep 20 11:18

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.